Clinical Trial

A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of the study is to characterize the safety and tolerability of XB371. The dose-escalation cohorts and Part B of the expansion cohorts are non-randomized. Part A of the expansion cohorts is randomized.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-08-08; most recent amendment 2026-02-13.
Trial Details
NCT Number NCT07123103
Lead Sponsor Exelixis
Conditions Solid Tumors
Enrollment 150 participants
Start Date 2025-08-18
Primary Completion 2027-11 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-02-17